Exploring acenocoumarol and silodosin in non-small cell lung cancer: Insights into EGFR-linked signaling mechanisms
The drugs acenocoumarol and silodosin downregulate KRAS and ERK2 in both A549 cell lines and Xenograft model. KRAS and ERK2 are components of EGFR-associated signaling pathways. Hence, acenocoumarol and silodosin can be further explored as repurposed candidates in future preclinical and clinical studies.
Institutions
- Manipal Academy of Higher Education (IN)
Publication Details
- Journal
- F1000Research
- Published
- 2025-09-23
- DOI
- https://doi.org/10.12688/f1000research.157465.2
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Department of Science and Technology, Ministry of Science and Technology, India
- Indian Council of Medical Research
- Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education
- Science and Engineering Research Board